MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from debt
financings, net of debt...
$747,656K
Proceeds from exercise of
options
$763K
Net cash provided by
(used in) financing...
$390,829K
Canceled cashflow
$357,590K
Net increase
(decrease) in cash, cash...
$363,071K
Canceled cashflow
$27,758K
Payment of loan payable
-$255,000K
Purchase of treasury
stock
$99,992K
Financing costs paid
$2,598K
Increase in accounts
payable and accrued...
$34,016K
Stock-based compensation
$19,950K
Net income
$19,777K
Decrease (increase) in
other current assets
-$10,661K
Loss on
extinguishment of debt
-$9,153K
Deferred income taxes
$3,864K
Noncash change in lease
liability and right of use...
$573K
Amortization of debt issuance
costs
$285K
Change in fair value of
notes payable
-$88K
Amortization of leasehold
interest
$48K
Depreciation and
amortization
$32K
Proceeds from maturity of
held-to-maturity securities
$11,250K
Net cash used in
operating activities
-$17,894K
Net cash used in
investing activities
-$9,864K
Canceled cashflow
$98,447K
Canceled cashflow
$11,250K
Increase in accounts
receivable
$86,418K
Investment in
held-to-maturity securities
$21,063K
Increase in inventory
$13,275K
(decrease) increase in
income taxes payable
-$6,718K
(decrease) increase in
deferred revenue
-$5,988K
Decrease in other current
liabilities
-$1,617K
Change in fair value of
equity investments
$1,534K
Decrease in lease
liabilities
-$424K
Amortization of premium
(discount) on investment...
$367K
Purchases of property,
plant and equipment
$51K
Back
Back
Cash Flow
TG Therapeutics BRIUMVI Approval Call Slide Deck 12
TG THERAPEUTICS, INC. (TGTX)
TG Therapeutics BRIUMVI Approval Call Slide Deck 12
TG THERAPEUTICS, INC. (TGTX)
source: myfinsight.com